Moreover, as aberrations in G-protein activating subunits have been shown to act as driver mutations implicated in multiple cancers [42], the use of siRNA to target and downregulate mutated GNAQ (degree = 8) in several cancers, in particular melanoma, has been also explored [43]. The gene discussed is GNAQ; the disease is cancer.